ALS-FTD Research Briefs: P62 Gene’s Role and Screening Tool for ALS-FTD
Research news items on the role of the p62 gene in ALS-FTD and the ALS-FTD-Q, a new screening tool for assessing behavioral disturbances in ALS
By Amy Madsen, originally posted at MDA/ALS NewsMagazine, September 26, 2012
Article Highlights:
The finding that mutations in the p62 gene can cause frontotemporal lobar degeneration, added to an earlier finding that such [...]
Categories: Research News
| 
Tags: ALS, ALS community, ALS research, ALS treatments, ALS-FTD, ALS-FTD-Q, amyotrophic lateral sclerosis, autophagy., Bob Stehlin, charged multivesicular body protein 2B, CHMP2B), chromosome 9 open reading frame 72 (C9ORF72), Columbia University College of Physicians & Surgeons, common pathway, dysarthria, frontotemporal dementia FTD, frontotemporal lobar degeneration (FTLD), fused in sarcoma (FUS), Lewis P. Rowland, Lou Gehrig's disease, Methodist Neurological Institute, Northwestern University Chicago, optineurin (OPTN), P62 gene, P62 gene in ALS and FTLD, PALS, progranulin (PGRN, pseudobulbar affect, RASCALS Foundation, Rob J. DeHaan, Robert A. Stehlin Campaign for ALS, sequestosome 1, SQSTM1 gene, St.Louis RASCALS ALS Lou Gehrig’s Disease amotrophic lateral sclerosis, Stanley H. Appel, tar DNA binding protein 43 (TDP43), Teepu Siddique, ubiquilin 2 (UBQLN2), University of Amsterdam, valosin-containing protein (VCP)
| 
No comments